Skip to main content

Aminoglutethimide Disease Interactions

There are 3 disease interactions with aminoglutethimide.

Major

Aminoglutethimide (applies to aminoglutethimide) adrenal insufficiency

Major Potential Hazard, High plausibility. Applicable conditions: Panhypopituitarism

Aminoglutethimide suppresses adrenal function and is indicated for the treatment of selected cases of Cushing's syndrome. It generally should not be used in patients with adrenocortical insufficiency.

References

  1. Box M, Saltissi D, Fawcett D (1986) "Inappropriate secretion of antidiuretic hormone following aminoglutethimide therapy." Br J Urol, 58, p. 724-5
  2. Bonneterre J, Nguyen M, Hecquet B, Cappelaere P (1984) "Aminoglutethimide-induced hypercholesterolaemia ." Lancet, 1, p. 912-3
  3. Davies JP, Bentley P, Ghose RR (1989) "Aminoglutethimide-induced hyperkalaemia." Br J Clin Pract, 43, p. 263-4
  4. Bork E, Hansen M (1986) "Severe hyponatremia following simultaneous administration of aminoglutethimide and diuretics." Cancer Treat Rep, 70, p. 689-90
  5. Santen RJ, Misbin RI (1981) "Aminoglutethimide: review of pharmacology and clinical use." Pharmacotherapy, 1, p. 95-120
  6. (2002) "Product Information. Cytadren (aminoglutethimide)." Ciba Self-Medication Inc
View all 6 references
Moderate

Aminoglutethimide (applies to aminoglutethimide) hypotension

Moderate Potential Hazard, High plausibility.

Aminoglutethimide suppresses aldosterone production by the adrenal cortex, which may result in orthostatic or persistent hypotension. Therapy with aminoglutethimide should be administered cautiously in patients with or predisposed to hypotension. Blood pressure should be monitored at regular intervals, and patients should be advised not to rise abruptly from a sitting or recumbent position. Mineralocorticoid replacement therapy may be necessary.

References

  1. (2002) "Product Information. Cytadren (aminoglutethimide)." Ciba Self-Medication Inc
Moderate

Aminoglutethimide (applies to aminoglutethimide) liver disease

Moderate Potential Hazard, Moderate plausibility.

Aminoglutethimide is primarily metabolized by the liver. Therefore, the clearance and therapeutic activity of the drug may be altered in patients with hepatic impairment. In addition, aminoglutethimide may cause elevated levels of transaminases, alkaline phosphatase, and bilirubin. Therapy with aminoglutethimide should be administered cautiously in patients with compromised hepatic function. Liver function tests should be performed and monitored more closely during therapy.

References

  1. Santen RJ, Misbin RI (1981) "Aminoglutethimide: review of pharmacology and clinical use." Pharmacotherapy, 1, p. 95-120
  2. (2002) "Product Information. Cytadren (aminoglutethimide)." Ciba Self-Medication Inc

Aminoglutethimide drug interactions

There are 265 drug interactions with aminoglutethimide.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer